Background:

Fexofenadine hydrochloride (MDL-16455 hydrochloride), a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial (person aged ≥16 years)[1].

Fexofenadine hydrochloride (MDL-16455 hydrochloride) (100 μM; 1 hour) effectively blocks phosphorylated p38 activation in histamine-induced nasal fibroblasts[2].

Fexofenadine hydrochloride (MDL-16455 hydrochloride) (5-20 mg/kg; oral daily for 3 weeks) dose-dependently suppresses eosinophilia in C57BL/6 mice infected with T. spiralis[1].

参考文献:
[1]. Watanabe N, et al. The effects of fexofenadine on eosinophilia and systemic anaphylaxis in mice infected with Trichinella spiralis. Int Immunopharmacol. 2004 Mar;4(3):367-75.
[2]. Park IH, et al. Histamine Promotes the Release of Interleukin-6 via the H1R/p38 and NF-κB Pathways in NasalFibroblasts. Allergy Asthma Immunol Res. 2014 Nov;6(6):567-72.